Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be ...
Investor's Business Daily on MSN
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug
Eli Lilly said Friday a combination using Verzenio reduced the risk of death by nearly 16% over two years for breast cancer ...
The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...
MedPage Today on MSN
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer
BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...
Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate ...
While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...
Lilly's Verzenio prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment: Indianapolis Monday, October 20, 2025, 12:00 Hrs [IST] Eli Lilly and ...
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback